Bioavailability (BA)/Bioequivalence (BE) Unit
The CBR’s role in ensuring the quality and efficacy of generic medicines is staggeringly important. The CBR’s BA/BE Unit at present is the only fully independent academe-based bioequivalence testing laboratory currently operational in the country. It is the first one to have been accredited by the Food and Drugs Administration as a collaborator in bioavailability studies in the Philippines, and it has also garnered the Center of Excellence award given by the United States Pharmacopeia. The BA/BE Unit conducts 2-3 studies a month and boasts of a 24-bed testing facility upgraded recently in July 2019.